Abstract. Aberrant DNA methylation occurs early and frequently in tumorigenesis. Identification of DNA methylation biomarkers is a field that provides potential for improving the clinical process of breast cancer diagnosis. We utilized a genome-wide technique, methylated DNA isolation assay (MeDIA), in combination with high-resolution CpG microarray analysis to identify hypermethylated genes in breast cancer. Among differentially methylated genes between tumor and adjacent normal tissues, 3 candidate genes (LHX2, WT1 and OTP) were finally selected through a step-wise filtering process and examined for methylation status in normal tissues, primary tumor, and paired adjacent normal-appearing tissues from 39 breast cancer patients. Based on the calculated cut-off values, all genes showed significantly higher frequencies of aberrant hypermethylation in primary tumors (43.6% for LHX2, 89.7% for WT1 and 100% for OTP, P<0.05) while frequencies were intermediate in paired adjacent normal tissues and absent in normal tissues. On further analysis, the methylation level in primary tumors was not significantly correlated with clinicopathological features. Interestingly, DNA methylation of a novel gene OTP was detected in adjacent normal tissues even 6 cm away from primary tumors, suggesting that OTP methylation may qualify as a biomarker for the early detection of breast cancer. In conclusion, we successfully identified a novel gene OTP frequently methylated in breast cancer by genomewide screening. Our results suggest that the OTP gene may play a crucial role in breast carcinogenesis, although further clinical validation will be needed to evaluate the potential application of OTP in the early detection of breast cancer.
Introduction
Breast cancer is the most frequently diagnosed cancer in women with 1.15 million cases reported worldwide every year (1, 2) . Higher quality mammography and magnetic resonance imaging have increased the detection of breast cancer leading to a overall decline in mortality. These screening procedures, however, may also lead to over diagnosis and result in unnecessary treatments and procedures (http://www.breastcancer. org/). Therefore, development of new screening tools with high accuracy would be of great value.
It is now widely recognized that aberrant epigenetic modifications play a crucial role in altering gene expression and inducing tumor formation (3, 4) . In recent years much attention has been paid to epigenetic gene silencing. This loss of gene transcription is due to hypermethylation of CpG islands in the promoter region and is known to frequently occur in the early stages of cancer development. These findings have suggested that such aberrant events could be utilized as molecular diagnostic biomarkers for early detection or risk identification for cancers (5) .
There have been several studies profiling gene methylation at a genomic level or using panels of known genes (6) (7) (8) (9) (10) (11) . These studies have attempted to define methylation sites in genes and determine their frequency of methylation in clinical samples, which may lead to their use in molecular diagnostic testing for early detection of breast cancer. However, these established cancer-associated genes do not yet have a sufficient usability to be considered efficient clinical diagnostic markers.
In the present study, we performed a CpG microarray analysis in conjunction with a proprietary method for enrichment of methylated DNA we developed, using optimally truncated methyl DNA binding domain (MBD2bt), named methylated DNA isolation assay (MeDIA) (12) . We used this system to characterize frequently methylated genes in early stage primary tumors and matched normal appearing tissues from breast cancer patients. Through step-wise filtering and subsequent verification of methylation-positivity in clinical Table I .
Genome-wide methylation microarray analysis. CpG microarray analysis in conjunction with the enrichment of methylated DNA by methylated DNA isolation assay (MeDIA) using optimally truncated methyl DNA binding domain (MBD2bt) was performed as previously described with slight modification (12) . The genomic DNA was isolated from samples taken from breast tumor blocks and their adjacent normal tissues of 3 patients (stage 1) and the equal amount of DNA was mixed. Briefly, 0.5 µg of sonic fragmented genomic DNA from primary tumor and their match-paired normal-appearing adjacent tissues was incubated with 2 µg of recombinant MBD2bt protein for 4 h at 4˚C with rocking platform, respectively. The enriched methylated DNA was amplified using whole genome amplification kit (GenomePlex ® , Sigma, USA) as recommended by the manufacturer. The common reference DNA (CRD) was prepared by amplifying genomic DNA from normal placenta control without enrichment as an internal control. Enriched methylated DNA and CRD were labeled with Cy5 and Cy3, respectively. The labeled DNA samples were purified by PCR purification kit (Qiagen, USA) and then co-hybridized to human CpG island microarrays containing 237,000 oligonucleotide probes covering 27,800 CpG islands (Agilent, Santa Clara Technologies, Inc., CA, USA) according to the manufacturer's instructions.
Microarray data analysis. The hybridized images were analyzed by Agilent DNA microarray Scanner (Agilent Technologies, Inc.) and the data quantification was performed using Feature Extraction software version 9.3.2.1 (Agilent Technologies, Inc.). Preprocessing of raw data and normalization steps were performed using GeneSpring 7.3.1 (Agilent Technologies, Inc.). The background-corrected intensity data were normalized using the intensity dependent LOWESS method to remove the dye bias within each array as recommended by the manufacturer (Agilent Technologies, Inc.). The relative methylation level of each probe between tumor and their adjacent normal tissues was calculated by comparison of ratio in each of enriched DNA/CRD. The multiple-probe enriched genes were selected as methylation target genes when their probes showed positive call ≥2.0-fold in methylation of tumor compared with paired adjacent normal tissues in at least two adjacent probes allowing a one-probe gap within the CpG islands.
The raw DNA microarray data were submitted for public access to the Gene Expression Omnibus (http://www.ncbi.nlm. nih.gov/geo/) and can be obtained using the accession number: GSE27374.
Methylation assessment by quantitative bisulfite-pyrosequencing. Bisulfite PCR and pyrosequencing primers were designed to amplify 3 to 5 CpG dinucleotide sites in the target regions of genes using PSQ Assay Design software (Biotage, Sweden). Sequences of primers used and PCR condition are given in Table II . Genomic DNA (200 ng) was modified by sodium bisulfate using the EZ DNA Methylation kit (Zymo Research, CA, USA) according to the manufacturer's instructions. Bisulfite-modified DNA was amplified in a 50 µl reaction with the primer set and Taq polymerase (Enzynomics, Daejeon, South Korea). The PCR amplification was run for 45 cycles with an optimal annealing temperature. The PCR products were visualized on 2% agarose gel electrophoresis by ethidium bromide staining.
Pyrosequencing was performed using the Pyro Gold kit and PSQ 96MA instrument (Qiagen, Hilden, Germany) as instructed by the manufacturer. The methylation index (MtI) of each gene in each sample was calculated as the average value of m C/( m C+C) for all examined CpGs in target regions. All experiments included samples without templates as negative control.
Statistical analysis. Statistical analysis was completed using the MedCalc software, version 9.3.2.0 (MedCalc, Mariakerke, Belgium). A P-value of <0.05 was considered as statistically significant. Wilcoxon Rank sum test was used to determine whether there were differences in methylation levels in tumors and adjacent normal tissues. The relationship between methylation level and clinicopathological features was analyzed by ANOVA test.
Results

Comprehensive methylation pattern analysis comparing primary breast tumors and matched-adjacent tissue.
To comprehensively investigate CpG sites of genes which are aberrantly methylated early in breast cancer, we compared the DNA methylation status of pooled genomic DNA from three primary tumors with match-paired normal-appearing adjacent tissue (hereby, termed adjacent normal) from stage I breast cancer patients by MEDIA-CpG microarray analysis (12) . Using this approach we observed that several hundred genes, including polycomb-target as a major group, demonstrated differential methylation between tumor and adjacent normal tissues. In order to reduce the number of genes and further verify methylation we adopted the following sequential filtering criteria: i) initial gene lists were chosen through an arbitrary selection process from probes in microarrays with signal intensities ≥2,000 in tumor tissue; ii) methylation levels were compared in tumor tissues and paired adjacent normal tissue, selected genes had higher (≥2.0-fold) levels of methylation in at least two adjacent probes allowing a one-probe gap within the CpG islands; and iii) genes not harboring CpG islands in the regulatory region were excluded (Fig. 1) . From this, we obtained 6 candidate genes, AXIN2, LHX2, NFIX, OTP, PTGER4 and WT1 for methylation assesment (Table III) .
Examination of methylation status of 6 candidates in cell lines and normal tissue.
We confirmed the methylation status of the 6 candidate genes derived by microarray analysis using a pyrosequencing assay in breast cancer cell lines MCF7 and MDA-MB-231 ( Fig. 2A) . In this assay, sodium bisulfite-treated genomic DNA is amplified by PCR using gene specific primer sets with methylation-independent sequences. We demonstrated that all genes appear to a have high level of methylation in both cell lines. We also examined the DNA methylation status in normal breast tissues from 6 healthy individuals. Three genes, AXIN2, NFIX, PTGER4 showed a relatively higher range of methylation level (MtI >33%) while the level of methylation of the remaining 3 genes, LHX2, OTP and WT1 were either lower range (MtI range from 11% to 20.6%) or unmethylated (MtI <10%) (Fig. 2B) . We then decide not to include AXIN2, NFIX, PTGER4 genes which had Mtl >33% in normal breast tissue, from further clinical validation studies assuming that they would not be able to meet necessary specificity standards in future testing.
Clinical validation of LHX2, OTP and WT1 genes in primary tumor and adjacent normal breast tissue.
To verify whether LHX2, OTP and WT1 genes are hypermethylated in primary breast tumors, we examined their methylation status in 39 primary breast tumors and matched-adjacent normal tissue from breast cancer patients representing stages I, II, and III as well as other clinicopathological parameters (Table I) . Most of the samples from cancer patients showed a higher methylation level of each gene in primary tumors when compared to matched normal tissue (61.5% for LHX2, 92.3% for WT1 and 100% for OTP).
We then used the highest methylation levels of each gene in normal samples as a cut-off value for methylation-positive calls. All genes showed a high frequency of methylation positivity in tumors (43.6% for LHX2, 89.7% for WT1 and 100% for OTP). We also observed that aberrant methylation of each gene existed in tumor-adjacent normal tissue, although the levels and frequencies were intermediate between those of tumor and normal tissues ( Fig. 3 and Table IV ). In addition, we investigated the potential relationship between methylation levels of LHX2, OTP and WT1 and clinicopathological parameters including patients' age, histological type, tumor size, histological grade, clinical stage, presence of lymph node metastases, steroid receptor (ER and PR) status and HER2 amplification. There were no significant correlations between methylation levels and any of the analyzed clinicopathological parameters (Table V) .
Discussion
The number of genes showing aberrant methylation in breast cancer is increasing, although only a few genes have demonstrated promise as methylation markers for early detection and risk assessment (13, 14) . To expand these findings to novel genes in breast cancer, both gene-specific and genomic-level methylation profiling approaches have been performed (6) (7) (8) (9) (10) (11) .
From among those approaches, Pfeifer and colleagues focused on finding new genes which are frequently found to be methylated in early on-set breast cancer. To accomplish this they used CpG microarray analysis in conjunction with the methylated CpG island recovery assay (MIRA), which is based on the affinity of a two protein complex (MBD2/ MBD3L1) attached to methylated DNA. Their data highlighted homeobox genes such as THX1, HOXB13 and HNF1B as new potential methylation biomarkers and demonstrated a high frequency of methylation in significant portion of breast cancers (10) .
In the present study, we employed a similar approach to screen differentially methylated CpG sites in primary tumor tissues and tumor-adjacent normal tissue of early stage breast cancer patients. However, we used an optimally truncated methylated DNA binding domain for the enrichment of methylated DNA (MBD2bt) instead of the MBD2/MBD3L1 complex (12) . We found that hundreds of genes are aberrantly methylated in early primary breast tumors. These genes were composed of previously reported and novel genes in breast cancer. From the methylated target genes of Tommasi and colleagues (10), we found that 60/81 genes matched our data in breast cancer. This observation suggested that our strategy for selection of putative methylation biomarkers was sound. For clinical validation, we narrowed down the number of genes to three, LHX2, WT1 and OTP, through step-wise selection procedure (described in the results section in this study) which demonstrated a higher level and frequency of methylation in these 3 genes in breast tumor tissue when compared to adjacent normal tissue.
Notably our finding of LHX2 and WT1, are also present in the previous gene list (10) , indicating that an affinity-based CpG methylation microarray with methylated DNA binding domain of MBD2t or MBD2/MBD3L1 complex is a powerful approach for global methylation mapping.
Considering that one of the ultimate goals of tumor specific molecular markers is to detect tumors non-invasively in an early stage of development, tumor-specific DNA methylation might be the appropriate candidate for this purpose since aberrant methylation at CpG islands occurs frequently and is an early epigenetic event in tumorigenesis (5, 15, 16) . Conceptually a promising methylation marker with the purpose of early cancer detection is thought to be retaining the tendency of methylation positivity across all tumor types, and from early to advanced states regardless of clincopathological status including stage. Some portion of cell-free DNA in serum or plasma is thought to have originated from tumor cells undergoing either apoptosis or necrosis in cancer patients (17) (18) (19) . Accordingly, identification of tumor-specifically methylated sites of genes is a critical step in the sequential process of molecular marker development for early cancer detection in body fluids including blood derivatives from breast cancer Table V . The relationship between clinicopathological parameters and MtIs of 3 genes in breast cancer samples. patients. Therefore, we postulate that the OTP gene would be a strong candidate marker for early detection considering its methylation frequency (sensitivity/specificity) and the early time of occurrence. First, this gene showed methylation in 100% of our 39 primary tumor samples. Second, although the level of methylation is lower than that of matched-primary tumor tissue, there is a high frequency of methylation positivity that clearly appears in 87% of tumor-adjacent normal tissue when given the cut-off values are used ( Fig. 3 and Table IV) .
To further assess the extent of aberrant methylation of the OTP gene in adjacent normal tissues, we examined the methylation status of the OTP gene quantitatively in 20 cases of available adjacent normal tissues at various distances away from the tumor lesion boarder. Aberrant methylation of the OTP gene was extended up to 6 cm away from the primary tumor (Fig. 4) . In addition, we could not find a significant correlation between OTP gene methylation status and various clinicopathological characteristics (Table V) . This suggests that this gene may gain aberrant methylation at a very early stage and be an indicator of predisposition in precancerous regions due to a field methylation effect.
Most gene methylation is barely detectable in the serum or plasma of healthy individuals. Recently, several groups, using a panel of multiple genes which are well known to be tumorassociated, have demonstrated the prevalence of methylation positive genes in sera or plasma from breast cancer patients (20) (21) (22) (23) (24) (25) (26) (27) . Nevertheless, current multiple gene panel assays still lack the necessary sensitivity for application in the clinical setting.
To our knowledge, the OTP gene has never been reported to be linked to DNA methylation modification in breast cancer.
Taken together, our findings strengthen the possibility of OTP gene methylation as a biomarker candidate for early detection of breast cancer. The OTP gene has been described to be important for brain development (28, 29) . In addition, Wu and colleagues have recently reported that OTP is frequently methylated in astrocytomas (30) . However, little is known about the biological function of this novel gene in cancer.
In summary, we demonstrated that microarray analysis using a minimum size of methylated DNA binding domain for methylated DNA enrichment successfully works for genomic level methylation profiling. With this approach we have identified the OTP gene which can provide an additive sensitivity to current set of candidate genes for early detection of breast cancer.
More sample validation and defining a specific region or regions of OTP that are methylated will be necessary to determine if the methylation status of this gene can be utilized as a biomarker for large scale, early detection of breast cancer. 
